Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Access of Momelotinib for Subjects With Myelofibrosis
NCT03441113Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- May 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 2 trial of mivavotinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by GSK. Started May 2018; status: active, not recruiting.
02
Drugs
mivavotinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT03441113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441113.